Get access

Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物:第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)

Authors


Correspondence

George Grunberger, Grunberger Diabetes Institute, 43494 Woodward Avenue, Suite 208, Bloomfield Hills, MI 48302, USA.

Tel: +1 248 335 7740

Fax: +1 248 977 4335

Email: grunberger@gdi-pc.com

Abstract

The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called “incretin defect” in patients with T2DM.

摘要

这篇简短的综述总结与更新了在过去的8年中引进的两类2型糖尿病治疗药物的临床经验: (i)胰高血糖素样肽-1受体激动剂;以及(ii)二肽基肽酶4抑制剂。这两种类型的药物都是针对T2DM患者的“肠促胰岛素缺陷”。

Ancillary